Copyright
©The Author(s) 2017.
World J Clin Oncol. Feb 10, 2017; 8(1): 1-20
Published online Feb 10, 2017. doi: 10.5306/wjco.v8.i1.1
Published online Feb 10, 2017. doi: 10.5306/wjco.v8.i1.1
Table 2 Chemotherapy agents for non-small-cell lung cancer by generation
| Generation | Agents | Effect on survival for stages II-III |
| First | Methotrexate Cyclophosphamide Vincristine Doxorubicin | No effect |
| Second | Cisplatin, cisplatin-based combinations Ifosfamide Mitomycin Vindesine Vinblastine Etoposide | Combination with radiation superior to radiation alone Concurrent superior than sequential chemotherapy and radiation |
| Third | Paclitaxel, paclitaxel-based combinations Docetaxel Gemcitabine Vinorelbine Irinotecan Topotecan | Expected to be superior to second generation agents given with radiation |
- Citation: Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8(1): 1-20
- URL: https://www.wjgnet.com/2218-4333/full/v8/i1/1.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i1.1